Efficacy, safety and the lymphocyte subsets changes of low-dose IL-2 in patients with systemic lupus erythematosus: A systematic review and meta-analysis.

Qin-Yi SuJing LuoXin-Miao WangJing-Kai DiYi-Xin CaoSheng-Xiao Zhang

Published in: Immunity, inflammation and disease (2024)

LD-IL-2 was promising and well-tolerated in treating SLE, which could promote Treg's proliferation and functional recovery. Injecting 0.5 million IU of IL-2 daily can better induce the differentiation of Treg cells and maintain immune homeostasis than injecting 1 million IU every other day.

Keyphrases

low dose
induced apoptosis
peripheral blood
systemic lupus erythematosus
signaling pathway
physical activity
cell cycle arrest
rheumatoid arthritis
disease activity
endoplasmic reticulum stress